Egon Zehnder’s Latest Global Board Diversity Tracker Shows Heightened Need for Inclusivity on Corporate Boards as They Diversify
14.11.2022 09:00:00 CET | Business Wire | Press Release
Egon Zehnder, the world’s leadership advisory firm, today released the results of its 2022-2023 Global Board Diversity Tracker, revealing that while corporate boards are seeing steady progress on gender and racial and ethnic diversity, more action is needed on the broader goal of inclusivity which will improve the effectiveness of increasingly diverse boards.
Highlights from the Tracker include:
- The number of major companies with at least one woman on board has risen to 93 percent from 89 percent in 2020.
- Fastest progress over past 10 years is dominated by Western European countries, but Australasia, Canada, South Africa and Malaysia have transformed their boards too.
- In the U.S., 19 percent of directorships among Russell 3000 companies were held by non-white board members, up from 13 percent in 2019, according to data analyzed from Institutional Shareholder Services.
These increases in board diversity have illuminated a new need – for those organizations that have prioritized diverse representation to now develop an inclusive board culture that enables new perspectives to be shared and valued. As boards face increasing external pressure to modernize their operations, board chairs will play an important role as champions of inclusion and board effectiveness, while continuing to expand the definition of diversity.
While every seat on a board is highly impactful, further progress is needed in diversifying board leadership representation:
- In 2022, 25 percent of board committee leaders globally were women, up from 21.2 in 2020. There also was a slight increase in non-executive chair positions held by female directors to 8.4 percent, up from 7.2 percent in 2020, and to 3.7 percent in the number of female executive chair positions, a 0.7 percent increase from 2020.
- According to our analysis of Institutional Shareholder Services data, non-white directors in the Russell 3000 held 19 percent of directorships in 2022 and 9 percent of board chair roles. At the committee level, 13 percent of non-white directors were audit, compensation or nominating and governance committee chairs.
“We continue to see positive progress in diversifying boards, but we must recognize the hard work has only just begun and an increased focus on inclusion will ultimately drive meaningful progress. While every board’s journey will be different, the destination should look similar: a board with an inclusive culture with directors who bring a mix of experience that integrate unique perspectives into every decision the board makes,” said Pam Warren, co-leader of the Global Diversity, Equity & Inclusion Practice at Egon Zehnder. “To get there, it’s time to shift our attention to driving inclusivity by rethinking the process, culture, and operations that define the fabric of our boards. This will require vulnerability, learning and a commitment to change but the results will have deep impact for years to come.”
LGBTQ+ diversity also remains underrepresented and often undefined on boards. An Out Leadership report found that less than 1 percent of Fortune 500 companies have inclusive policies aimed at LGBTQ+ leaders, and only 26 out of 5,670 board seats are held by LGBTQ+ leaders—several of which are held by the same person. The report also found that only 41 Fortune 1000 companies define board diversity as inclusive of LGBTQ+ individuals.
Since the last Global Board Diversity Tracker two years ago, however, some progress happened: In 2021, Nasdaq enacted board diversity requirements for its roughly 3,000 listed companies to hire at least one woman as well as a racially diverse or LGBTQ+ individual, in addition to requiring disclosure of the demographic makeup of their board directors. In Canada, provisions have been put in place to increase female representation on boards to 50 percent and other minority groups (including members of the LGBTQ+ community) to 30 percent within five and seven years, respectively.
“It’s encouraging to see progress in the right direction, especially in countries such as Canada where there are provisions in place aimed at increasing women and minority representation, which includes LGBTQ+,” said Cynthia Soledad, co-leader of the Diversity, Equity & Inclusion Practice at Egon Zehnder. “As boards transition from focusing solely on representation to also considering inclusion, it will be crucial to evolve all board processes to be more inclusive, including meeting norms, director onboarding, and board leadership succession planning. The board chair will play a critical role in making this transition toward action.”
For additional data and action plan for inclusion within corporate boards, view the full Global Board Diversity Tracker report: https://www.egonzehnder.com/global-board-diversity-tracker.
About the Global Board Diversity Tracker
Released biennially over the last 18 years, the report tracks and analyzes global board diversity progress. This year’s report analyzed a total of 19,958 boards seats – using data from 1,776 publicly-traded companies across 44 countries with a combined market capitalization of €8bn – organizations that have the influence and opportunity to drive economic and culture impact for entire societies, as well as individuals. As every board’s journey will be different, Egon Zehnder included in the report additional sectors of diversity, offering case studies with directors, chief executives, and chairs globally to discuss the inclusion of ethnicity, sexual orientation, and other perspectives in the boardroom.
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. We help organizations get to the heart of their leadership challenges and offer honest feedback and insights to help leaders realize their true being and purpose. Our 560 consultants across 63 offices and 37 countries are former industry and functional leaders who collaborate seamlessly across geographies, industries and functions to deliver the full power of the Firm to every client, every time.
We believe that together we can transform people, organizations and the world through leadership.
For more information, visit www.egonzehnder.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005034/en/
Contact information
Stacy Drumtra, Chicago
stacy.drumtra@egonzehnder.com | T: +1 312 260 8974
Martin Klusmann, Berlin
martin.klusmann@egonzehnder.com | T: +49 170 236 0101
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press Release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press Release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press Release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 22:42:00 CEST | Press Release
The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To mark its 95th anniversary, the Empire State Building will debut new experiences
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 22:17:00 CEST | Press Release
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important drugs to patients earlier. Fast Track designation enables frequent communication with the FDA to discuss the drug's development plan and ensure collection o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
